Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Assets Average (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Assets Average for 4 consecutive years, with $32.0 million as the latest value for Q4 2025.

  • Quarterly Assets Average rose 55.63% to $32.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.0 million through Dec 2025, up 55.63% year-over-year, with the annual reading at $37.9 million for FY2023, N/A changed from the prior year.
  • Assets Average for Q4 2025 was $32.0 million at Neuphoria Therapeutics, up from $28.0 million in the prior quarter.
  • The five-year high for Assets Average was $37.8 million in Q2 2023, with the low at $20.5 million in Q4 2024.
  • Average Assets Average over 4 years is $27.7 million, with a median of $26.9 million recorded in 2024.
  • The sharpest move saw Assets Average soared 59.01% in 2023, then increased 8.27% in 2025.
  • Over 4 years, Assets Average stood at $23.7 million in 2022, then skyrocketed by 59.01% to $37.8 million in 2023, then tumbled by 45.6% to $20.5 million in 2024, then skyrocketed by 55.63% to $32.0 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $32.0 million, $28.0 million, and $29.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.